Eisai to Present Latest Data on Lemborexant at World Sleep Congress
TOKYO, Sep, 19 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that latest data on lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of sleep-wake disorders, including insomnia and Irregular Sleep-Wake Rhythm Disorder (ISWRD) associated with Alzheimer's disease/dementia will be presented at World Sleep Congress (World Sleep 2019), from September 20 to 25 in Vancouver, Canada.
At this congress, oral presentations will be given including the first congress presentation about the analysis of results at the end of 12 months from phase III clinical study (SUNRISE-2) evaluating long-term effectiveness and safety of lemborexant in patients with insomnia and the effect on sleep architecture in older adults with insomnia from phase III clinical study (SUNRISE-1) evaluating the efficacy and safety of lemborexant. Furthermore, one more oral presentation for nonclinical research about efficacy of lemborexant with ISWRD model mouse will be held. In addition, six poster presentations, including on the effect of lemborexant on fatigue by patient-reported outcomes from the 6-month placebo-controlled treatment period of SUNRISE-2 as a subgroup analysis will be given.
Lemborexant acts on the orexin neurotransmitter system and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythm.
Lemborexant is being developed for the treatment of sleep-wake disorders including insomnia disorder, and Eisai has submitted new drug applications seeking approval of lemborexant for use in the treatment of insomnia disorder in the United States (December 2018), Japan (March 2019), and Canada (August 2019), respectively. Additionally, a Phase II clinical study of lemborexant in patients with ISWRD associated with mild to moderate Alzheimer's dementia is underway. For the ongoing clinical studies, please visit clinicaltrials.gov.
Through the development of lemborexant, Eisai aims for contribution for rework/recovery by bringing an active daytime life by fast sleep onset and good quality sleep to patients suffering from sleep-wake disorders including insomnia, and is striving to further contribute to satisfying unmet medical needs and improve the benefits to patients and their families.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.
In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.
For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.
Public Relations Department,
Eisai Co., Ltd.
Copyright ©2019 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.